6XXV

Crystal Structure of a computationally designed Immunogen S2_1.2 in complex with its elicited antibody C57


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.209 
  • R-Value Observed: 0.210 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

De novo protein design enables the precise induction of RSV-neutralizing antibodies.

Sesterhenn, F.Yang, C.Bonet, J.Cramer, J.T.Wen, X.Wang, Y.Chiang, C.I.Abriata, L.A.Kucharska, I.Castoro, G.Vollers, S.S.Galloux, M.Dheilly, E.Rosset, S.Corthesy, P.Georgeon, S.Villard, M.Richard, C.A.Descamps, D.Delgado, T.Oricchio, E.Rameix-Welti, M.A.Mas, V.Ervin, S.Eleouet, J.F.Riffault, S.Bates, J.T.Julien, J.P.Li, Y.Jardetzky, T.Krey, T.Correia, B.E.

(2020) Science 368

  • DOI: 10.1126/science.aay5051
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • De novo protein design has been successful in expanding the natural protein repertoire. However, most de novo proteins lack biological function, presenting a major methodological challenge. In vaccinology, the induction of precise antibody responses ...

    De novo protein design has been successful in expanding the natural protein repertoire. However, most de novo proteins lack biological function, presenting a major methodological challenge. In vaccinology, the induction of precise antibody responses remains a cornerstone for next-generation vaccines. Here, we present a protein design algorithm called TopoBuilder, with which we engineered epitope-focused immunogens displaying complex structural motifs. In both mice and nonhuman primates, cocktails of three de novo-designed immunogens induced robust neutralizing responses against the respiratory syncytial virus. Furthermore, the immunogens refocused preexisting antibody responses toward defined neutralization epitopes. Overall, our design approach opens the possibility of targeting specific epitopes for the development of vaccines and therapeutic antibodies and, more generally, will be applicable to the design of de novo proteins displaying complex functional motifs.


    Organizational Affiliation

    Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Antibody C57, Heavy ChainA, D251Homo sapiensMutation(s): 0 
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Antibody C57, Light ChainB, E233Homo sapiensMutation(s): 0 
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
S2_1.2C, F124Homo sapiensMutation(s): 0 
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.209 
  • R-Value Observed: 0.210 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 241.019α = 90
b = 66.89β = 110.811
c = 91.384γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Swiss National Science FoundationSwitzerland2015/333
European CommissionEuropean Union716058
Swiss National Science FoundationSwitzerland310030-163139

Revision History 

  • Version 1.0: 2020-04-22
    Type: Initial release
  • Version 1.1: 2020-05-06
    Changes: Database references
  • Version 1.2: 2020-05-27
    Changes: Database references